{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:07Z","timestamp":1761513487120,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"UCB Pharma"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.eplepsyres.2014.06.018","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T21:30:24Z","timestamp":1404595824000},"page":"1385-1391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Adjunctive lacosamide\u20145 Years\u2019 clinical experience"],"prefix":"10.1016","volume":"108","author":[{"given":"Linda J.","family":"Stephen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0005","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.epilep.2012.07.002","article-title":"How clinically useful are regulatory trials with new antiepileptic drugs","volume":"1","author":"Brodie","year":"2013","journal-title":"Epileptology"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bcp.12176","article-title":"Meta-analysis of antiepileptic drugs for refractory partial (focal) epilepsy: an observation","volume":"76","author":"Brodie","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B* 1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","article-title":"Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK)","volume":"21","author":"Flores","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1528-1167.2012.03543.x","article-title":"Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-na\u00efve patients with partial-onset seizures","volume":"54","author":"Fountain","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.seizure.2011.08.005","article-title":"Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures","volume":"20","author":"Garcia-Morales","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u0103sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0050","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1523\/JNEUROSCI.5747-03.2004","article-title":"Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis","volume":"24","author":"Hao","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0055","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eplepsyres.2011.09.010","article-title":"Initial post marketing experience with lacosamide in adult patients with epilepsy","volume":"98","author":"Harden","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0060","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extensions trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0404.2012.01704.x","article-title":"Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre","volume":"127","author":"Kamel","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.yebeh.2011.02.006","article-title":"Atrioventricular block following lacosamide intoxication","volume":"20","author":"Krause","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1528-1167.2009.02463.x","article-title":"Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures","volume":"51","author":"Krauss","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0085","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"L\u0151scher","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0090","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0095","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0100","first-page":"436","article-title":"Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation","volume":"91","author":"Niespodziany","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0105","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/j.1528-1167.2011.03212.x","article-title":"Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy","volume":"52","author":"Nizam","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2010.10.002","article-title":"Lacosamide neurotoxicity with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction","volume":"20","author":"Novy","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","article-title":"Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation","volume":"106","author":"Novy","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0120","first-page":"297","article-title":"Genome-wide association study identifies HLA-A* 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Ozeki","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0125","first-page":"113","article-title":"Adjunctive lacosamide in clinical practice: a multicentre prospective study in Spain by the Central Spain Lacosamide Study Group","volume":"78","author":"Para-Gomez","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0130","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","article-title":"The mechanism of action of valproate in neuropsychiatric disorders: can we see the forest for the trees","volume":"64","author":"Rosenberg","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0135","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical data grouped by mechanisms of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0140","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/epi.12237","article-title":"Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice","volume":"54","author":"Shandra","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yebeh.2011.07.035","article-title":"Adjunctive lacosamide in clinical practice\u2013sodium blockade with a difference","volume":"22","author":"Stephen","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","article-title":"Antiepileptic drug monotherapy versus polytherapy\u2014Pursuing seizure freedom and tolerability","volume":"25","author":"Stephen","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0155","unstructured":"UK Food Guide.net, 2013. E132. Indigo Carmine, Indigotine, FD&C Blue 2 \u3008http:\/\/www.ukfoodguide.net\/e132.htm\u3009."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0160","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1517\/14656566.2012.713347","article-title":"Lacosamide in patients with pharmacoresistant epilepsy","volume":"13","author":"Verrotti","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Von Elm","year":"2007","journal-title":"Br. Med. J."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0175","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yebeh.2009.07.043","article-title":"Six months of postmarketing experience with adjunctive lacosmide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy centre in Germany","volume":"16","author":"Wehner","year":"2009","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.06.018_bib0180","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"Zwarenstein","year":"2008","journal-title":"Br. Med. J."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114001764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114001764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:32:10Z","timestamp":1760275930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121114001764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0920121114001764"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.06.018","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive lacosamide\u20145 Years\u2019 clinical experience","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}